An Expert Consensus to Standardise Definitions, Diagnosis and Treatment Targets for Anti-fibrotic Stricture Therapies in Crohn's Disease

Overview

Journal Aliment Pharmacol Ther

Specialties Gastroenterology
Pharmacology

Date 2018 Jun 20

PMID 29920726

Citations 91

Authors

F Rieder

D Bettenworth

C Ma

C E Parker

L A Williamson

S A Nelson

G Van Assche

A di Sabatino

Y Bouhnik

R W Stidham

A Dignass

G Rogler

S A Taylor

J Stoker

J Rimola

M E Baker

J G Fletcher

J Panes

W J Sandborn

B G Feagan

V Jairath

Affiliations

Soon will be listed here.

Abstract

Background: Fibrotic stricture is a common complication of Crohn's disease (CD) affecting approximately half of all patients. No specific anti-fibrotic therapies are available; however, several therapies are currently under evaluation. Drug development for the indication of stricturing CD is hampered by a lack of standardised definitions, diagnostic modalities, clinical trial eligibility criteria, endpoints and treatment targets in stricturing CD.

Aim: To standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Chron's disease.

Methods: An interdisciplinary expert panel consisting of 15 gastroenterologists and radiologists was assembled. Using modified RAND/University of California Los Angeles appropriateness methodology, 109 candidate items derived from systematic review and expert opinion focusing on small intestinal strictures were anonymously rated as inappropriate, uncertain or appropriate. Survey results were discussed as a group before a second and third round of voting.

Results: Fibrotic strictures are defined by the combination of luminal narrowing, wall thickening and pre-stenotic dilation. Definitions of anastomotic (at site of prior intestinal resection with anastomosis) and naïve small bowel strictures were similar; however, there was uncertainty regarding wall thickness in anastomotic strictures. Magnetic resonance imaging is considered the optimal technique to define fibrotic strictures and assess response to therapy. Symptomatic strictures are defined by abdominal distension, cramping, dietary restrictions, nausea, vomiting, abdominal pain and post-prandial abdominal pain. Need for intervention (endoscopic balloon dilation or surgery) within 24-48 weeks is considered the appropriate endpoint in pharmacological trials.

Conclusions: Consensus criteria for diagnosis and response to therapy in stricturing Crohn's disease should inform both clinical practice and trial design.

Citing Articles

Imaging diagnosis of cryptogenic multifocal ulcerous stenosing enteritis.

Zhang X, Ma L, Xiao M, Qin J, Zhou M, Yang H Insights Imaging. 2025; 16(1):55.

PMID: 40055223 PMC: 11889280. DOI: 10.1186/s13244-025-01931-9.

Discrimination between Inflammatory and Fibrotic Activity in Crohn's Disease-Associated Ileal-Colonic Anastomotic Strictures by Combined Ga-68-FAPI-46 and F-18-FDG-PET/CT Imaging.

Beck M, Kuwert T, Atzinger A, Gerner M, Hartmann A, Saake M Visc Med. 2025; 41(1):1-13.

PMID: 39927190 PMC: 11801851. DOI: 10.1159/000542160.

Surgery time for stenosed Crohn's disease: Case report.

Nofal M, Yousef A, Samarah S, Al-Qudah B Int J Surg Case Rep. 2025; 127:110903.

PMID: 39874808 PMC: 11808665. DOI: 10.1016/j.ijscr.2025.110903.

Discordance between MR enterography and endoscopic detection of Crohn's disease ileal strictures: evidence to inform recommendations.

Yalon M, Mohammadinejad P, Inoue A, Takahashi H, Ehman E, Esquivel A Abdom Radiol (NY). 2024; .

PMID: 39692760 DOI: 10.1007/s00261-024-04721-x.

Endoscopic dilation of small-intestine strictures in Crohn's disease by balloon-assisted enteroscopy: a systematic review and meta-analysis.

Moond V, Gill V, Malik S, Kasture A, Parajuli S, Soni S Ann Gastroenterol. 2024; 37(6):682-694.

PMID: 39568704 PMC: 11574157. DOI: 10.20524/aog.2024.0920.

References

Bettenworth D, Rieder F . Medical therapy of stricturing Crohn's disease: what the gut can learn from other organs - a systematic review. Fibrogenesis Tissue Repair. 2014; 7(1):5. PMC: 4230721. DOI: 10.1186/1755-1536-7-5. View

Jairath V, Levesque B, Vande Casteele N, Khanna R, Mosli M, Hindryckx P . Evolving Concepts in Phases I and II Drug Development for Crohn's Disease. J Crohns Colitis. 2016; 11(2):246-255. DOI: 10.1093/ecco-jcc/jjw137. View

Bruining D, Zimmermann E, Loftus Jr E, Sandborn W, Sauer C, Strong S . Consensus Recommendations for Evaluation, Interpretation, and Utilization of Computed Tomography and Magnetic Resonance Enterography in Patients With Small Bowel Crohn's Disease. Radiology. 2018; 286(3):776-799. DOI: 10.1148/radiol.2018171737. View

King Jr T, Bradford W, Castro-Bernardini S, Fagan E, Glaspole I, Glassberg M . A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22):2083-92. DOI: 10.1056/NEJMoa1402582. View

Rieder F, Latella G, Magro F, Yuksel E, Higgins P, Di Sabatino A . European Crohn's and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn's Disease. J Crohns Colitis. 2016; 10(8):873-85. DOI: 10.1093/ecco-jcc/jjw055. View

Peyrin-Biroulet L, Sandborn W, Sands B, Reinisch W, Bemelman W, Bryant R . Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 2015; 110(9):1324-38. DOI: 10.1038/ajg.2015.233. View

Sconfienza L, Cavallaro F, Colombi V, Pastorelli L, Tontini G, Pescatori L . In-vivo Axial-strain Sonoelastography Helps Distinguish Acutely-inflamed from Fibrotic Terminal Ileum Strictures in Patients with Crohn's Disease: Preliminary Results. Ultrasound Med Biol. 2016; 42(4):855-63. DOI: 10.1016/j.ultrasmedbio.2015.11.023. View

Thia K, Sandborn W, Harmsen W, Zinsmeister A, Loftus Jr E . Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology. 2010; 139(4):1147-55. PMC: 2950117. DOI: 10.1053/j.gastro.2010.06.070. View

Yaffe B, Korelitz B . Prognosis for nonoperative management of small-bowel obstruction in Crohn's disease. J Clin Gastroenterol. 1983; 5(3):211-5. DOI: 10.1097/00004836-198306000-00003. View

10.

Quaia E, De Paoli L, Stocca T, Cabibbo B, Casagrande F, Cova M . The value of small bowel wall contrast enhancement after sulfur hexafluoride-filled microbubble injection to differentiate inflammatory from fibrotic strictures in patients with Crohn's disease. Ultrasound Med Biol. 2012; 38(8):1324-32. DOI: 10.1016/j.ultrasmedbio.2012.04.008. View

11.

Rimola J, Planell N, Rodriguez S, Delgado S, Ordas I, Ramirez-Morros A . Characterization of inflammation and fibrosis in Crohn's disease lesions by magnetic resonance imaging. Am J Gastroenterol. 2015; 110(3):432-40. DOI: 10.1038/ajg.2014.424. View

12.

Fumery M, Pineton de Chambrun G, Stefanescu C, Buisson A, Bressenot A, Beaugerie L . Detection of Dysplasia or Cancer in 3.5% of Patients With Inflammatory Bowel Disease and Colonic Strictures. Clin Gastroenterol Hepatol. 2015; 13(10):1770-5. DOI: 10.1016/j.cgh.2015.04.185. View

13.

Richeldi L, du Bois R, Raghu G, Azuma A, Brown K, Costabel U . Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22):2071-82. DOI: 10.1056/NEJMoa1402584. View

14.

Farmer R, HAWK W, TURNBULL Jr R . Clinical patterns in Crohn's disease: a statistical study of 615 cases. Gastroenterology. 1975; 68(4 Pt 1):627-35. View

15.

Takenaka K, Ohtsuka K, Kitazume Y, Nagahori M, Fujii T, Saito E . Comparison of magnetic resonance and balloon enteroscopic examination of the small intestine in patients with Crohn's disease. Gastroenterology. 2014; 147(2):334-342.e3. DOI: 10.1053/j.gastro.2014.04.008. View

16.

Rieder F, de Bruyn J, Pham B, Katsanos K, Annese V, Higgins P . Results of the 4th scientific workshop of the ECCO (Group II): markers of intestinal fibrosis in inflammatory bowel disease. J Crohns Colitis. 2014; 8(10):1166-78. DOI: 10.1016/j.crohns.2014.03.009. View

17.

Rieder F, Fiocchi C, Rogler G . Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases. Gastroenterology. 2016; 152(2):340-350.e6. PMC: 5209279. DOI: 10.1053/j.gastro.2016.09.047. View

18.

Neurath M . Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol. 2017; 14(5):269-278. DOI: 10.1038/nrgastro.2016.208. View

19.

Oberhuber G, Stangl P, Vogelsang H, Schober E, Herbst F, Gasche C . Significant association of strictures and internal fistula formation in Crohn's disease. Virchows Arch. 2000; 437(3):293-7. DOI: 10.1007/s004280000226. View

20.

Bettenworth D, Gustavsson A, Atreja A, Lopez R, Tysk C, Van Assche G . A Pooled Analysis of Efficacy, Safety, and Long-term Outcome of Endoscopic Balloon Dilation Therapy for Patients with Stricturing Crohn's Disease. Inflamm Bowel Dis. 2016; 23(1):133-142. DOI: 10.1097/MIB.0000000000000988. View